http://rdf.ncbi.nlm.nih.gov/pubchem/reference/21073128

Outgoing Links

Predicate Object
contentType Journal Article
issn 2162-3619
issueIdentifier 1
pageRange 9-
publicationName Experimental Hematology & Oncology
startingPage 9
bibliographicCitation Nakamura N, Kasahara S, Kitagawa J, Nakamura H, Sawada M, Fukuno K, Shibata Y, Kaneda Y, Hara T, Kanemura N, Tsurumi H, Shimizu M. A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma. Experimental Hematology & Oncology. 2022 Feb 25;11(1):9. doi: 10.1186/s40164-022-00264-3.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ad4e4db4d3c0e90f7c483caa3353a9ba
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c95bfe12ba95e4a1a009008c1874d65d
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0003-1682-7777
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8b9d4d5919a5af4bc190c23c2770087
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2fa5c7b179ea36137929639ad6229d98
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c043605c9850f3ef1bfb12fb85a0f9b9
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e183ed285a833c968acda8804f5fc363
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_25f97308e000be7ad017bbd5189ef8c1
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a6586a9d8e0ebeaa4a8137aae7565e27
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6973426304a704559c9e03b0e60b0a39
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1eafc70e37a14f0a437a681da29661e3
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7ad3bff5ad234effb908718993715d2b
date 2022-02-25^^<http://www.w3.org/2001/XMLSchema#date>
identifier https://pubmed.ncbi.nlm.nih.gov/35216626
https://pubmed.ncbi.nlm.nih.gov/PMC8876747
https://doi.org/10.1186/s40164-022-00264-3
isPartOf https://portal.issn.org/resource/ISSN/2162-3619
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/40664
language English
source https://scigraph.springernature.com/
https://www.crossref.org/
https://pubmed.ncbi.nlm.nih.gov/
title A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8389
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID65628
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID10603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9408
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6253
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7947
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_f762fe2442e70fe54d540f3fd4225b55

Showing number of triples: 1 to 39 of 39.